Pharma Equity Group A/S Cl A - Asset Resilience Ratio

Latest as of June 2019: 2.24%

Pharma Equity Group A/S Cl A (PEG) has an Asset Resilience Ratio of 2.24% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Pharma Equity Group A/S Cl A's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Dkr1.72 Million

≈ $269.58K USD Cash + Short-term Investments

Total Assets

Dkr77.09 Million

≈ $12.06 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2008–2018)

This chart shows how Pharma Equity Group A/S Cl A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PEG asset base.

Liquid Assets Composition Over Time

This chart breaks down Pharma Equity Group A/S Cl A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Pharma Equity Group A/S Cl A for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Dkr0.00	0%
Short-term Investments	Dkr1.72 Million	2.24%
Total Liquid Assets	Dkr1.72 Million	2.24%

Asset Resilience Insights

Limited Liquidity: Pharma Equity Group A/S Cl A maintains only 2.24% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Pharma Equity Group A/S Cl A Industry Peers by Asset Resilience Ratio

Compare Pharma Equity Group A/S Cl A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Pharma Equity Group A/S Cl A (2008–2018)

The table below shows the annual Asset Resilience Ratio data for Pharma Equity Group A/S Cl A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2018-09-30	2.13%	Dkr1.72 Million ≈ $269.58K	Dkr80.84 Million ≈ $12.65 Million	+1.06pp
2016-09-30	1.07%	Dkr1.35 Million ≈ $210.90K	Dkr125.75 Million ≈ $19.67 Million	-0.27pp
2015-09-30	1.34%	Dkr1.69 Million ≈ $264.10K	Dkr126.25 Million ≈ $19.75 Million	-5.61pp
2012-09-30	6.95%	Dkr35.00 Million ≈ $5.48 Million	Dkr503.85 Million ≈ $78.83 Million	+0.05pp
2011-09-30	6.89%	Dkr35.00 Million ≈ $5.48 Million	Dkr507.76 Million ≈ $79.44 Million	-69.48pp
2008-09-30	76.37%	Dkr199.84 Million ≈ $31.27 Million	Dkr261.67 Million ≈ $40.94 Million	--

pp = percentage points

About Pharma Equity Group A/S Cl A

CO:PEG Denmark Biotechnology

Market Cap

$15.17 Million

Dkr96.98 Million DKK

Market Cap Rank

#26044 Global

#115 in Denmark

Share Price

Dkr0.08

Change (1 day)

-1.25%

52-Week Range

Dkr0.07 - Dkr0.14

All Time High

Dkr2.81